Immunotherapy Program at Northside

Northside Hospital’s Immunotherapy Program is a nationally recognized treatment center.

Northside Hospital’s Immunotherapy and CAR T-cell Program FACTS:

  • Within five to ten business days of the initial referral, the relapsed or refractory non-Hodgins’s lymphoma patient, acute lymphocytic leukemia, or multiple myeloma patient will be evaluated by the Northside Hospital’s immunotherapy and CAR T-cell physicians.

  • Dedicated cellular therapy clinical coordinators will organize and coordinate care from new patient consultation through treatment follow-up.

  • With onsite apheresis capabilities at Atlanta Blood Services, our team is able to schedule T-cell apheresis within days of a new patient's consultation.

  • Dedicated financial team that is able to expeditiously obtain financial approval for all immunotherapy treatments, including CAR T-cell.

  • Continuous communication with referring hematologists and oncologists to ensure bridging therapy is initiated if necessary.

  • Please visit immunotherapy clinical trials for a listing of leukemia, multiple myeloma, diffuse large B-cell lymphoma, and other various disease-specific immunotherapy trials.

B-CELL MALIGNANCIES

Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat B-cell malignancies:

  • BREYANZI™ For adult patients with:

    • Relapsed or refractory (R/R) large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B and are refractory to first-line chemoimmunotherapy, relapsed within 12 months of first-line chemoimmunotherapy or after two or more lines of systemic therapy.

    • Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.

    • Relapsed or refractory (R/R) mantle cell lymphoma after two or more lines of systemic therapy, including a BTK inhibitor.

    • Relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), after two or more lines of systemic therapy, including a BTK inhibitor and a BCL-2 inhibitor.

  • KYMRIAH® For adult patients with:

    • Relapsed or refractory (R/R) large B-cell lymphoma, including DLBCL not otherwise specified, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma, and after two or more lines of systemic therapy.

    • Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.

  • TECARTUS™ For adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

  • YESCARTA® For adult patients with:

    • Relapsed or refractory (R/R) large B-cell lymphoma, refractory to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy.

    • Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy. 

    • Relapsed or refractory (R/R) aggressive large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, DLBCL arising from follicular lymphoma (FL), and after two or more lines of systemic therapy.

Available Commercial CAR T-cell Products:

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat acute lymphoblastic leukemia (ALL):

  • AUCATZYL®: For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

    • CAR T product is given in 2 doses - the treatment regimen consists of a split dose infusion to be administered on Day 1 and Day 10 (± 2 days) (2.1). Dose to be administered is determined by the patient's bone marrow blast assessment.

  • KYMRIAH®: For patients up to 25 years old with B-cell precursor acute lymphoblastic leukemia (ALL) where ALL is refractory or in a second or later relapse.

  • TECARTUS™: For adult patients with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL).

MULTIPLE MYELOMA

Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat multiple myeloma:

  • ABECMA®: For adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

    *Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR-T eligibility. Please contact the Hematological Malignancy Coordinator at BloodCancerCoord@northside.com, Office: 470-945-8745 or Fax: 404-255-1939.

  • CARVYKTI®: For adult patients with relapsed or refractory (R/R) multiple myeloma after one (1) or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and are refractory to lenalidomide.

    *Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR-T eligibility. Please contact the Hematological Malignancy Coordinator at BloodCancerCoord@northside.com, Office: 470-945-8745 or Fax: 404-255-1939.

How to Refer BMT, Leukemia or Immunotherapy patient